The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours

I. A. Burney, S. B. Field, R. J. Maxwell, J. R. Griffiths, CRC Biomedical Magnetic Resonance Research Group

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Using31P NMR spectroscopy, changes in tumour metabolic status were studied in a transplanted rat fibrosarcoma following the administration of vasodilators. Mean Arterial Blood Pressure (MABP) was monitored simultaneously. Two vasodilators were studied, prazosin and CGRP, which altered the NMR parameters Pi/∑P, βNTP, Pi, PCr/Pi and PME/Pi in a dose dependent manner. There was a good correlation between the various NMR papameters; for analysis, Pi/ZP was used for convenience. With increasing doses of vasodilator, Pi/ZP increased and the MABP decreased. Reduction in pHNMR showed a correlation with decreasing MABP following the administration of prazosin but not after CGRP. Both prazosin and CGRP produced changes in31P NMR spectra consistent with a reduction in tumour blood flow. The results for prazosin and CGRP were comparable and showed a 15-20% increase in Pi/ZP for a 20% reduction in MABP. These results were compared with those from hydralazine. With hydralazine an acceptable reduction in blood pressure (up to ≈25%) has little effect and may even alter NMR parameters consistent with an increase in blood flow, a reduction of ≈40% is required for a significant decrease in flow.Both prazosin and CGRP are shown to be far more effective than hydralazine in causing tumour hypoxia at a clinically acceptable reduction in blood pressure. CGRP may be the more suitable for clinical use because of its short half life, its capability to achieve controlled hypotension and the relatively few side effects associated with its use.

Original languageEnglish
Pages (from-to)683-688
Number of pages6
JournalBritish Journal of Cancer
Volume64
Issue number4
DOIs
Publication statusPublished - 1991

Fingerprint

Calcitonin Gene-Related Peptide
Prazosin
Arterial Pressure
Hydralazine
Vasodilator Agents
Controlled Hypotension
Blood Pressure
Tumor Hypoxia
Fibrosarcoma
Half-Life
Neoplasms
Magnetic Resonance Spectroscopy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Burney, I. A., Field, S. B., Maxwell, R. J., Griffiths, J. R., & CRC Biomedical Magnetic Resonance Research Group (1991). The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours. British Journal of Cancer, 64(4), 683-688. https://doi.org/10.1038/bjc.1991.381

The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours. / Burney, I. A.; Field, S. B.; Maxwell, R. J.; Griffiths, J. R.; CRC Biomedical Magnetic Resonance Research Group.

In: British Journal of Cancer, Vol. 64, No. 4, 1991, p. 683-688.

Research output: Contribution to journalArticle

Burney, IA, Field, SB, Maxwell, RJ, Griffiths, JR & CRC Biomedical Magnetic Resonance Research Group 1991, 'The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours', British Journal of Cancer, vol. 64, no. 4, pp. 683-688. https://doi.org/10.1038/bjc.1991.381
Burney, I. A. ; Field, S. B. ; Maxwell, R. J. ; Griffiths, J. R. ; CRC Biomedical Magnetic Resonance Research Group. / The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours. In: British Journal of Cancer. 1991 ; Vol. 64, No. 4. pp. 683-688.
@article{4c2b6c6622c44bbb91fed5701489b0fe,
title = "The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours",
abstract = "Using31P NMR spectroscopy, changes in tumour metabolic status were studied in a transplanted rat fibrosarcoma following the administration of vasodilators. Mean Arterial Blood Pressure (MABP) was monitored simultaneously. Two vasodilators were studied, prazosin and CGRP, which altered the NMR parameters Pi/∑P, βNTP, Pi, PCr/Pi and PME/Pi in a dose dependent manner. There was a good correlation between the various NMR papameters; for analysis, Pi/ZP was used for convenience. With increasing doses of vasodilator, Pi/ZP increased and the MABP decreased. Reduction in pHNMR showed a correlation with decreasing MABP following the administration of prazosin but not after CGRP. Both prazosin and CGRP produced changes in31P NMR spectra consistent with a reduction in tumour blood flow. The results for prazosin and CGRP were comparable and showed a 15-20{\%} increase in Pi/ZP for a 20{\%} reduction in MABP. These results were compared with those from hydralazine. With hydralazine an acceptable reduction in blood pressure (up to ≈25{\%}) has little effect and may even alter NMR parameters consistent with an increase in blood flow, a reduction of ≈40{\%} is required for a significant decrease in flow.Both prazosin and CGRP are shown to be far more effective than hydralazine in causing tumour hypoxia at a clinically acceptable reduction in blood pressure. CGRP may be the more suitable for clinical use because of its short half life, its capability to achieve controlled hypotension and the relatively few side effects associated with its use.",
author = "Burney, {I. A.} and Field, {S. B.} and Maxwell, {R. J.} and Griffiths, {J. R.} and {CRC Biomedical Magnetic Resonance Research Group}",
year = "1991",
doi = "10.1038/bjc.1991.381",
language = "English",
volume = "64",
pages = "683--688",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours

AU - Burney, I. A.

AU - Field, S. B.

AU - Maxwell, R. J.

AU - Griffiths, J. R.

AU - CRC Biomedical Magnetic Resonance Research Group

PY - 1991

Y1 - 1991

N2 - Using31P NMR spectroscopy, changes in tumour metabolic status were studied in a transplanted rat fibrosarcoma following the administration of vasodilators. Mean Arterial Blood Pressure (MABP) was monitored simultaneously. Two vasodilators were studied, prazosin and CGRP, which altered the NMR parameters Pi/∑P, βNTP, Pi, PCr/Pi and PME/Pi in a dose dependent manner. There was a good correlation between the various NMR papameters; for analysis, Pi/ZP was used for convenience. With increasing doses of vasodilator, Pi/ZP increased and the MABP decreased. Reduction in pHNMR showed a correlation with decreasing MABP following the administration of prazosin but not after CGRP. Both prazosin and CGRP produced changes in31P NMR spectra consistent with a reduction in tumour blood flow. The results for prazosin and CGRP were comparable and showed a 15-20% increase in Pi/ZP for a 20% reduction in MABP. These results were compared with those from hydralazine. With hydralazine an acceptable reduction in blood pressure (up to ≈25%) has little effect and may even alter NMR parameters consistent with an increase in blood flow, a reduction of ≈40% is required for a significant decrease in flow.Both prazosin and CGRP are shown to be far more effective than hydralazine in causing tumour hypoxia at a clinically acceptable reduction in blood pressure. CGRP may be the more suitable for clinical use because of its short half life, its capability to achieve controlled hypotension and the relatively few side effects associated with its use.

AB - Using31P NMR spectroscopy, changes in tumour metabolic status were studied in a transplanted rat fibrosarcoma following the administration of vasodilators. Mean Arterial Blood Pressure (MABP) was monitored simultaneously. Two vasodilators were studied, prazosin and CGRP, which altered the NMR parameters Pi/∑P, βNTP, Pi, PCr/Pi and PME/Pi in a dose dependent manner. There was a good correlation between the various NMR papameters; for analysis, Pi/ZP was used for convenience. With increasing doses of vasodilator, Pi/ZP increased and the MABP decreased. Reduction in pHNMR showed a correlation with decreasing MABP following the administration of prazosin but not after CGRP. Both prazosin and CGRP produced changes in31P NMR spectra consistent with a reduction in tumour blood flow. The results for prazosin and CGRP were comparable and showed a 15-20% increase in Pi/ZP for a 20% reduction in MABP. These results were compared with those from hydralazine. With hydralazine an acceptable reduction in blood pressure (up to ≈25%) has little effect and may even alter NMR parameters consistent with an increase in blood flow, a reduction of ≈40% is required for a significant decrease in flow.Both prazosin and CGRP are shown to be far more effective than hydralazine in causing tumour hypoxia at a clinically acceptable reduction in blood pressure. CGRP may be the more suitable for clinical use because of its short half life, its capability to achieve controlled hypotension and the relatively few side effects associated with its use.

UR - http://www.scopus.com/inward/record.url?scp=0025768214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025768214&partnerID=8YFLogxK

U2 - 10.1038/bjc.1991.381

DO - 10.1038/bjc.1991.381

M3 - Article

VL - 64

SP - 683

EP - 688

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -